1
|
Penas C, Arroyo-Berdugo Y, Apraiz A, Rasero J, Muñoa-Hoyos I, Andollo N, Cancho-Galán G, Izu R, Gardeazabal J, Ezkurra PA, Subiran N, Alvarez-Dominguez C, Alonso S, Bosserhoff AK, Asumendi A, Boyano MD. Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression. Sci Rep 2023; 13:9561. [PMID: 37308689 DOI: 10.1038/s41598-023-36684-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 06/08/2023] [Indexed: 06/14/2023] Open
Abstract
Originally considered to act as a transcriptional co-factor, Pirin has recently been reported to play a role in tumorigenesis and the malignant progression of many tumors. Here, we have analyzed the diagnostic and prognostic value of Pirin expression in the early stages of melanoma, and its role in the biology of melanocytic cells. Pirin expression was analyzed in a total of 314 melanoma biopsies, correlating this feature with the patient's clinical course. Moreover, PIR downregulated primary melanocytes were analyzed by RNA sequencing, and the data obtained were validated in human melanoma cell lines overexpressing PIR by functional assays. The immunohistochemistry multivariate analysis revealed that early melanomas with stronger Pirin expression were more than twice as likely to develop metastases during the follow-up. Transcriptome analysis of PIR downregulated melanocytes showed a dampening of genes involved in the G1/S transition, cell proliferation, and cell migration. In addition, an in silico approach predicted that JARID1B as a potential transcriptional regulator that lies between PIR and its downstream modulated genes, which was corroborated by co-transfection experiments and functional analysis. Together, the data obtained indicated that Pirin could be a useful marker for the metastatic progression of melanoma and that it participates in the proliferation of melanoma cells by regulating the slow-cycling JARID1B gene.
Collapse
Affiliation(s)
- Cristina Penas
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
| | - Yoana Arroyo-Berdugo
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
| | - Aintzane Apraiz
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
| | - Javier Rasero
- Department of Psychology, Carnegie Mellon University, Pittsburg, PA, 15213, USA
| | - Iraia Muñoa-Hoyos
- Department of Physiology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
| | - Noelia Andollo
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
| | | | - Rosa Izu
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
- Department of Dermatology, Basurto University Hospital, 48013, Bilbo, Spain
| | - Jesús Gardeazabal
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
- Department of Dermatology, Cruces University Hospital, 48903, Barakaldo, Spain
| | - Pilar A Ezkurra
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
| | - Nerea Subiran
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
- Department of Physiology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
| | - Carmen Alvarez-Dominguez
- MEDONLINE Multidisciplinary Research Group, Faculty of Health Sciences and Faculty of Education, International University of La Rioja, 26006, Logroño, Spain
| | - Santos Alonso
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
- Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940, Leioa, Spain
| | - Anja K Bosserhoff
- Institute of Biochemistry, Friedrich-Alexander University of Erlangen-Nürnberg, 91054, Erlangen, Germany
- Comprehensive Cancer Center (CCC) Erlangen-EMN, 91054, Erlangen, Germany
| | - Aintzane Asumendi
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain
| | - María D Boyano
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, 48940, Leioa, Spain.
- Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Spain.
| |
Collapse
|
2
|
Malaina I, Gonzalez-Melero L, Martínez L, Salvador A, Sanchez-Diez A, Asumendi A, Margareto J, Carrasco-Pujante J, Legarreta L, García MA, Pérez-Pinilla MB, Izu R, Martínez de la Fuente I, Igartua M, Alonso S, Hernandez RM, Boyano MD. Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design. Int J Mol Sci 2023; 24:ijms24109024. [PMID: 37240369 DOI: 10.3390/ijms24109024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/16/2023] [Accepted: 05/17/2023] [Indexed: 05/28/2023] Open
Abstract
In the last few years, the importance of neoantigens in the development of personalized antitumor vaccines has increased remarkably. In order to study whether bioinformatic tools are effective in detecting neoantigens that generate an immune response, DNA samples from patients with cutaneous melanoma in different stages were obtained, resulting in a total of 6048 potential neoantigens gathered. Thereafter, the immunological responses generated by some of those neoantigens ex vivo were tested, using a vaccine designed by a new optimization approach and encapsulated in nanoparticles. Our bioinformatic analysis indicated that no differences were found between the number of neoantigens and that of non-mutated sequences detected as potential binders by IEDB tools. However, those tools were able to highlight neoantigens over non-mutated peptides in HLA-II recognition (p-value 0.03). However, neither HLA-I binding affinity (p-value 0.08) nor Class I immunogenicity values (p-value 0.96) indicated significant differences for the latter parameters. Subsequently, the new vaccine, using aggregative functions and combinatorial optimization, was designed. The six best neoantigens were selected and formulated into two nanoparticles, with which the immune response ex vivo was evaluated, demonstrating a specific activation of the immune response. This study reinforces the use of bioinformatic tools in vaccine development, as their usefulness is proven both in silico and ex vivo.
Collapse
Affiliation(s)
- Iker Malaina
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
| | - Lorena Gonzalez-Melero
- NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
- Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain
| | - Luis Martínez
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- Luis Martínez, Basque Center for Applied Mathematics BCAM, 48009 Bilbao, Spain
| | - Aiala Salvador
- NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
- Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain
- Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Institute of Health Carlos III, 28029 Madrid, Spain
| | - Ana Sanchez-Diez
- Department of Dermatology, Basurto University Hospital, 48013 Bilbao, Spain
- Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain
| | - Aintzane Asumendi
- Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
| | - Javier Margareto
- Technological Services Division, Health and Quality of Life, TECNALIA, 01510 Miñano, Spain
| | - Jose Carrasco-Pujante
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- Luis Martínez, Basque Center for Applied Mathematics BCAM, 48009 Bilbao, Spain
| | - Leire Legarreta
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- Luis Martínez, Basque Center for Applied Mathematics BCAM, 48009 Bilbao, Spain
| | - María Asunción García
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- Luis Martínez, Basque Center for Applied Mathematics BCAM, 48009 Bilbao, Spain
| | - Martín Blas Pérez-Pinilla
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- Luis Martínez, Basque Center for Applied Mathematics BCAM, 48009 Bilbao, Spain
| | - Rosa Izu
- Department of Dermatology, Basurto University Hospital, 48013 Bilbao, Spain
- Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain
| | - Ildefonso Martínez de la Fuente
- Department of Mathematics, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
- Luis Martínez, Basque Center for Applied Mathematics BCAM, 48009 Bilbao, Spain
- CEBAS-CSIC Institute, Department of Nutrition, 30100 Murcia, Spain
| | - Manoli Igartua
- NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
- Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain
- Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Institute of Health Carlos III, 28029 Madrid, Spain
| | - Santos Alonso
- Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
| | - Rosa Maria Hernandez
- NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
- Bioaraba, NanoBioCel Research Group, 01009 Vitoria-Gasteiz, Spain
- Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Institute of Health Carlos III, 28029 Madrid, Spain
| | - María Dolores Boyano
- Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain
| |
Collapse
|
3
|
Falkenhain-López D, Muniesa C, Estrach MT, Morillo-Andújar M, Peñate Y, Acebo E, Pujol RM, García-Muret MP, Machan S, Medina S, Botella-Estrada R, Fernández de Misa R, Blanes M, Flórez A, Pérez-Paredes G, Izu R, Yanguas I, Silva-Díaz E, Pérez-Ferriols A, Prieto-Torres L, Zayas A, Parera-Amer ME, Pérez A, Aspe L, Román C, Sánchez-Caminero MP, Bassas-Vila J, Domínguez-Auñón JD, Calzado L, Navedo M, Ortiz-Prieto A, Servitje O, Polo-Rodríguez I, Torres I, Hernández-Hernández MN, Mitxelena-Eceiza J, García-Vázquez A, García-Doval I, Ortiz-Romero PL. [Translated article] Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermosifiliogr 2023; 114:T291-T298. [PMID: 36848951 DOI: 10.1016/j.ad.2022.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Accepted: 11/12/2022] [Indexed: 02/27/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Primary cutaneous lymphomas (PCL) are uncommon. Observations based on the first year of data from the Spanish Registry of Primary Cutaneous Lymphomas (RELCP, in its Spanish abbreviation) of the Spanish Academy of Dermatology and Venereology (AEDV) were published in February 2018. This report covers RELCP data for the first 5 years. PATIENTS AND METHODS RELCP data were collected prospectively and included diagnosis, treatments, tests, and the current status of patients. We compiled descriptive statistics of the data registered during the first 5 years. RESULTS Information on 2020 patients treated at 33 Spanish hospitals had been included in the RELCP by December 2021. Fifty-nine percent of the patients were men; the mean age was 62.2 years. The lymphomas were grouped into 4 large diagnostic categories: mycosis fungoides/Sézary syndrome, 1112 patients (55%); primary B-cell cutaneous lymphoma, 547 patients (27.1%); primary CD30+ lymphoproliferative disorders, 222 patients (11%), and other T-cell lymphomas, 116 patients (5.8%). Nearly 75% of the tumors were registered in stage I. After treatment, 43.5% achieved complete remission and 27% were stable at the time of writing. Treatments prescribed were topical corticosteroids (1369 [67.8%]), phototherapy (890 patients [44.1%]), surgery (412 patients [20.4%]), and radiotherapy (384 patients [19%]). CONCLUSION The characteristics of cutaneous lymphomas in Spain are similar to those reported for other series. The large size of the RELCP registry at 5 years has allowed us to give more precise descriptive statistics than in the first year. This registry facilitates the clinical research of the AEDV's lymphoma interest group, which has already published articles based on the RELCP data.
Collapse
Affiliation(s)
- D Falkenhain-López
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain.
| | - C Muniesa
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M T Estrach
- Departamento de Dermatología, Hospital Clínico, IDIBAPS, Universitario de Barcelona, Barcelona, Spain
| | - M Morillo-Andújar
- Departamento de Dermatología, Hospital Virgen del Rocío, Sevilla, Spain
| | - Y Peñate
- Departamento de Dermatología, Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Spain
| | - E Acebo
- Departamento de Dermatología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
| | - R M Pujol
- Departamento de Dermatología, Hospital del Mar, Barcelona, Spain
| | - M P García-Muret
- Departamento de Dermatología, Hospital Santa Creu i Sant Pau, UAB Barcelona, Barcelona, Spain
| | - S Machan
- Departamento de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - S Medina
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - R Botella-Estrada
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, Spain
| | - R Fernández de Misa
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
| | - M Blanes
- Departamento de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain
| | - A Flórez
- Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - G Pérez-Paredes
- Departamento de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander Cantabria, Spain
| | - R Izu
- Departamento de Dermatología, Hospital Universitario de Basurto, Bilbao, Bizkaia, Spain
| | - I Yanguas
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, Spain
| | - E Silva-Díaz
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - A Pérez-Ferriols
- Departamento de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain
| | - L Prieto-Torres
- Departamento de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - A Zayas
- Departamento de Dermatología, Hospital Universitario Dr. Peset, Valencia, Spain
| | - M E Parera-Amer
- Departamento de Dermatología, Hospital Universitario Son Llàtzer, Palma, Islas Baleares, Spain
| | - A Pérez
- Departamento de Dermatología, Hospital Universitario Nuestra Señora De Valme, Sevilla, Spain
| | - L Aspe
- Departamento de Dermatología, Hospital Universitario de Araba, Vitoria-Gasteiz, Álava, Spain
| | - C Román
- Departamento de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain
| | - M P Sánchez-Caminero
- Departamento de Dermatología, Hospital General de Ciudad Real, Ciudad Real, Spain
| | - J Bassas-Vila
- Departamento de Dermatología, Hospital Germans Trias i Pujol, Barcelona, Spain
| | - J D Domínguez-Auñón
- Departamento de Dermatología, Hospital Universitario del Henares, Coslada, Madrid, Spain
| | - L Calzado
- Departamento de Dermatología, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain
| | - M Navedo
- Departamento de Dermatología, Complejo Asistencial Universitario de León, León, Spain
| | - A Ortiz-Prieto
- Departamento de Dermatología, Hospital Puerta del Mar, Cádiz, Spain
| | - O Servitje
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - I Polo-Rodríguez
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - I Torres
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, Spain
| | - M N Hernández-Hernández
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
| | - J Mitxelena-Eceiza
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, Spain
| | - A García-Vázquez
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - I García-Doval
- Unidad de Investigación, Fundación Piel Sana AEDV, León, Spain; Departamento de Dermatología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
| | - P L Ortiz-Romero
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
4
|
Malaina I, Martínez L, Montoya JM, Alonso S, Boyano MD, Asumendi A, Izu R, Sanchez-Diez A, Cancho-Galan G, M. de la Fuente I. A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma. Life (Basel) 2023; 13:life13010155. [PMID: 36676104 PMCID: PMC9867041 DOI: 10.3390/life13010155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 01/02/2023] [Accepted: 01/03/2023] [Indexed: 01/06/2023]
Abstract
Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time.
Collapse
Affiliation(s)
- Iker Malaina
- Department of Mathematics, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
- Correspondence:
| | - Luis Martínez
- Department of Mathematics, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
| | - Juan Manuel Montoya
- Department of Mathematics, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
- Faculty of Basic Sciences, University of Pamplona, Pamplona 6800, Colombia
| | - Santos Alonso
- Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
| | - María Dolores Boyano
- Department of Cell Biology and Histology, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
- Biocruces Bizkaia Health Research Institute, 48903 Bizkaia, Spain
| | - Aintzane Asumendi
- Department of Cell Biology and Histology, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
- Biocruces Bizkaia Health Research Institute, 48903 Bizkaia, Spain
| | - Rosa Izu
- Biocruces Bizkaia Health Research Institute, 48903 Bizkaia, Spain
- Department of Dermatology, Basurto University Hospital, 48013 Bizkaia, Spain
| | - Ana Sanchez-Diez
- Biocruces Bizkaia Health Research Institute, 48903 Bizkaia, Spain
- Department of Dermatology, Basurto University Hospital, 48013 Bizkaia, Spain
| | - Goikoane Cancho-Galan
- Biocruces Bizkaia Health Research Institute, 48903 Bizkaia, Spain
- Department of Pathology, Basurto University Hospital, 48013 Bizkaia, Spain
| | - Ildefonso M. de la Fuente
- Department of Mathematics, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain
- CEBAS-CSIC Institute, Department of Nutrition, 30100 Murcia, Spain
| |
Collapse
|
5
|
Falkenhain-López D, Muniesa C, Estrach MT, Morillo-Andújar M, Peñate Y, Acebo E, Pujol RM, García-Muret MP, Machan S, Medina S, Botella-Estrada R, Fernández de Misa R, Blanes M, Flórez A, Pérez-Paredes G, Izu R, Yanguas I, Silva-Díaz E, Pérez-Ferriols A, Prieto-Torres L, Zayas A, Parera-Amer ME, Pérez A, Aspe L, Román C, Sánchez-Caminero MP, Bassas-Vila J, Domínguez-Auñón JD, Calzado L, Navedo M, Ortiz-Prieto A, Servitje O, Polo-Rodríguez I, Torres I, Hernández-Hernández MN, Mitxelena-Eceiza J, García-Vázquez A, García-Doval I, Ortiz-Romero PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermosifiliogr 2022; 114:291-298. [PMID: 36529273 DOI: 10.1016/j.ad.2022.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 11/09/2022] [Accepted: 11/12/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Primary cutaneous lymphomas (PCL) are uncommon. Observations based on the first year of data from the Spanish Registry of Primary Cutaneous Lymphomas (RELCP, in its Spanish abbreviation) of the Spanish Academy of Dermatology and Venereology (AEDV) were published in February 2018. This report covers RELCP data for the first 5 years. PATIENTS AND METHODS RELCP data were collected prospectively and included diagnosis, treatments, tests, and the current status of patients. We compiled descriptive statistics of the data registered during the first 5 years. RESULTS Information on 2020 patients treated at 33 Spanish hospitals had been included in the RELCP by December 2021. Fifty-nine percent of the patients were men; the mean age was 62.2 years. The lymphomas were grouped into 4 large diagnostic categories: mycosis fungoides/Sézary syndrome, 1112 patients (55%); primary B-cell cutaneous lymphoma, 547 patients (27.1%); primary CD30+lymphoproliferative disorders, 222 patients (11%), and other T-cell lymphomas, 116 patients (5.8%). Nearly 75% of the tumors were registered in stage I. After treatment, 43.5% achieved complete remission and 27% were stable at the time of writing. Treatments prescribed were topical corticosteroids (1369 [67.8%]), phototherapy (890 patients [44.1%]), surgery (412 patients [20.4%]), and radiotherapy (384 patients [19%]). CONCLUSION The characteristics of cutaneous lymphomas in Spain are similar to those reported for other series. The large size of the RELCP registry at 5 years has allowed us to give more precise descriptive statistics than in the first year. This registry facilitates the clinical research of the AEDV's lymphoma interest group, which has already published articles based on the RELCP data.
Collapse
Affiliation(s)
- D Falkenhain-López
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España.
| | - C Muniesa
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - M T Estrach
- Departamento de Dermatología, Hospital Clínico, IDIBAPS, Universitario de Barcelona, Barcelona, España
| | - M Morillo-Andújar
- Departamento de Dermatología, Hospital Virgen del Rocío, Sevilla, España
| | - Y Peñate
- Departamento de Dermatología, Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, España
| | - E Acebo
- Departamento de Dermatología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, España
| | - R M Pujol
- Departamento de Dermatología, Hospital del Mar, Barcelona, España
| | - M P García-Muret
- Departamento de Dermatología, Hospital Santa Creu i Sant Pau, UAB Barcelona, Barcelona, España
| | - S Machan
- Departamento de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
| | - S Medina
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, España
| | - R Botella-Estrada
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, España
| | - R Fernández de Misa
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, España
| | - M Blanes
- Departamento de Dermatología, Hospital General Universitario de Alicante, Alicante, España
| | - A Flórez
- Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España
| | - G Pérez-Paredes
- Departamento de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander Cantabria, España
| | - R Izu
- Departamento de Dermatología, Hospital Universitario de Basurto, Bilbao, Bizkaia, España
| | - I Yanguas
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, España
| | - E Silva-Díaz
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, España
| | - A Pérez-Ferriols
- Departamento de Dermatología, Hospital General Universitario de Valencia, Valencia, España
| | - L Prieto-Torres
- Departamento de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
| | - A Zayas
- Departamento de Dermatología, Hospital Universitario Dr. Peset, Valencia, España
| | - M E Parera-Amer
- Departamento de Dermatología, Hospital Universitario Son Llàtzer, Palma, Islas Baleares, España
| | - A Pérez
- Departamento de Dermatología, Hospital Universitario Nuestra Señora De Valme, Sevilla, España
| | - L Aspe
- Departamento de Dermatología, Hospital Universitario de Araba, Vitoria-Gasteiz, Álava, España
| | - C Román
- Departamento de Dermatología, Hospital Universitario de Salamanca, Salamanca, España
| | - M P Sánchez-Caminero
- Departamento de Dermatología, Hospital General de Ciudad Real, Ciudad Real, España
| | - J Bassas-Vila
- Departamento de Dermatología, Hospital Germans Trias i Pujol, Barcelona, España
| | - J D Domínguez-Auñón
- Departamento de Dermatología, Hospital Universitario del Henares, Coslada, Madrid, España
| | - L Calzado
- Departamento de Dermatología, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, España
| | - M Navedo
- Departamento de Dermatología, Complejo Asistencial Universitario de León, León, España
| | - A Ortiz-Prieto
- Departamento de Dermatología, Hospital Puerta del Mar, Cádiz, España
| | - O Servitje
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - I Polo-Rodríguez
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, España
| | - I Torres
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, España
| | - M N Hernández-Hernández
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, España
| | - J Mitxelena-Eceiza
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, España
| | - A García-Vázquez
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, España
| | - I García-Doval
- Unidad de Investigación, Fundación Piel Sana AEDV, León, España; Departamento de Dermatología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España
| | - P L Ortiz-Romero
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España
| |
Collapse
|
6
|
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, De la Cruz Vicente F, Machan S, Moya-Martínez C, Rovira R, Sanchez-Gonzalez B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, de Misa RF, Flórez A, Izu R, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero PL, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00634-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
7
|
Sánchez-Velázquez A, Bauer-Alonso A, Estrach T, Vega-Díez D, Garcia-Muret P, Haya L, Peñate Y, Acebo E, Fernández de Misa R, Blanes M, Suh-Oh HJ, Izu R, Silva-Díaz E, Sarriugarte J, Román-Curto C, Botella-Estrada R, Mateu-Puchades A, Prieto-Torres L, Morillas V, Morillo M, Sánchez-Caminero P, Calzado L, Pérez-Ferriols A, Pérez A, Domínguez JD, Navedo M, Muniesa C, Combalia A, Arroyo-Andrés J, Descalzo MA, García-Doval I, Ortiz-Romero PL. Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2021; 35:e624-e626. [PMID: 34062018 PMCID: PMC8242655 DOI: 10.1111/jdv.17430] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A Sánchez-Velázquez
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital Universitario 12 de Octubre, University Complutense, Madrid, Spain
| | - A Bauer-Alonso
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - T Estrach
- Department of Dermatology, IDIBAPS, Hospital Clinico, University of Barcelona, Barcelona, Spain
| | - D Vega-Díez
- Department of Dermatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - P Garcia-Muret
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain
| | - L Haya
- Department of Dermatology, Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Y Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas, Spain
| | - E Acebo
- Department of Dermatology, Hospital Universitario de Cruces, Bizkaia, Spain
| | - R Fernández de Misa
- Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - M Blanes
- Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
| | - H J Suh-Oh
- SERGAS-UVIGO, DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Pontevedra, Spain
| | - R Izu
- Department of Dermatology, Hospital Universitario Basurto, Bizkaia, Spain
| | - E Silva-Díaz
- Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - J Sarriugarte
- Department of Dermatology, Complejo Hospitalario de Navarra, Navarra, Spain
| | - C Román-Curto
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - R Botella-Estrada
- Department of Dermatology, Hospital Universitario la Fé, Valencia, Spain
| | - A Mateu-Puchades
- Department of Dermatology, Hospital Universitario Dr. Peset, Valencia, Spain
| | - L Prieto-Torres
- Department of Dermatology, Hospital Universitario Lozano Blesa, Valencia, Spain
| | - V Morillas
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Zaragoza, Spain
| | - M Morillo
- Department of Dermatology, Hospital Universitario Virgen de Rocío, Barcelona, Spain
| | - P Sánchez-Caminero
- Department of Dermatology, Hospital General Universitario de Ciudad Real, Sevilla, Spain
| | - L Calzado
- Department of Dermatology, Hospital Universitario de Torrejón, Ciudad Real, Spain
| | - A Pérez-Ferriols
- Department of Dermatology, Hospital General Universitario de Valencia, Madrid, Spain
| | - A Pérez
- Department of Dermatology, Hospital Universitario Nuestra Señora De Valme, Valencia, Spain
| | - J D Domínguez
- Department of Dermatology, Hospital Universitario del Henares, Sevilla, Spain
| | - M Navedo
- Department of Dermatology, Complejo Asistencial Universitario de León, Madrid, Spain
| | - C Muniesa
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - A Combalia
- Department of Dermatology, IDIBAPS, Hospital Clinico, University of Barcelona, Barcelona, Spain
| | - J Arroyo-Andrés
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital Universitario 12 de Octubre, University Complutense, Madrid, Spain
| | - M A Descalzo
- Unidad de Investigación, Fundación Piel Sana AEDV, León, Spain
| | - I García-Doval
- Unidad de Investigación, Fundación Piel Sana AEDV, León, Spain.,Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital Universitario 12 de Octubre, University Complutense, Madrid, Spain
| |
Collapse
|
8
|
Rivera R, Martorell A, López A, Salgado L, Sahuquillo A, de la Cueva P, Herranz P, Ratón JA, Ferrán M, Izu R, Ruiz-Genao D, García-Donoso C, Carrascosa JM. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. J Eur Acad Dermatol Venereol 2020; 35:e65-e67. [PMID: 32648955 DOI: 10.1111/jdv.16809] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- R Rivera
- Dermatology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
| | - A Martorell
- Dermatology Department, Hospital de Manises, Valencia, Spain
| | - A López
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - L Salgado
- Dermatology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - A Sahuquillo
- Dermatology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - P de la Cueva
- Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - P Herranz
- Dermatology Department, Hospital Universitario La Paz, Madrid, Spain
| | - J A Ratón
- Dermatology Department, Hospital Universitario de Cruces, Bilbao, Spain
| | - M Ferrán
- Dermatology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | - R Izu
- Dermatology Department, Hospital de Basurto, Bilbao, Spain
| | - D Ruiz-Genao
- Dermatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - C García-Donoso
- Dermatology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
| | - J M Carrascosa
- Dermatology Department, Hospital Universitari Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Barcelona, Spain
| |
Collapse
|
9
|
Mancuso F, Lage S, Rasero J, Díaz-Ramón JL, Apraiz A, Pérez-Yarza G, Ezkurra PA, Penas C, Sánchez-Diez A, García-Vazquez MD, Gardeazabal J, Izu R, Mujika K, Cortés J, Asumendi A, Boyano MD. Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study. Mol Oncol 2020; 14:1705-1718. [PMID: 32485045 PMCID: PMC7400797 DOI: 10.1002/1878-0261.12732] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2019] [Revised: 04/10/2020] [Accepted: 05/27/2020] [Indexed: 12/11/2022] Open
Abstract
Metastasis development represents an important threat for melanoma patients, even when diagnosed at early stages and upon removal of the primary tumor. In this scenario, determination of prognostic biomarkers would be of great interest. Serum contains information about the general status of the organism and therefore represents a valuable source for biomarkers. Thus, we aimed to define serological biomarkers that could be used along with clinical and histopathological features of the disease to predict metastatic events on the early‐stage population of patients. We previously demonstrated that in stage II melanoma patients, serum levels of dermcidin (DCD) were associated with metastatic progression. Based on the relevance of the immune response on the cancer progression and the recent association of DCD with local and systemic immune response against cancer cells, serum DCD was analyzed in a new cohort of patients along with interleukin 4 (IL‐4), IL‐6, IL‐10, IL‐17A, interferon γ (IFN‐γ), transforming growth factor‐β (TGF‐ β), and granulocyte–macrophage colony‐stimulating factor (GM‐CSF). We initially recruited 448 melanoma patients, 323 of whom were diagnosed as stages I‐II according to AJCC. Levels of selected cytokines were determined by ELISA and Luminex, and obtained data were analyzed employing machine learning and Kaplan–Meier techniques to define an algorithm capable of accurately classifying early‐stage melanoma patients with a high and low risk of developing metastasis. The results show that in early‐stage melanoma patients, serum levels of the cytokines IL‐4, GM‐CSF, and DCD together with the Breslow thickness are those that best predict melanoma metastasis. Moreover, resulting algorithm represents a new tool to discriminate subjects with good prognosis from those with high risk for a future metastasis.
Collapse
Affiliation(s)
- Filippo Mancuso
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain
| | - Sergio Lage
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain
| | - Javier Rasero
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.,Department of Psychology, Carnegie Mellon University, Pittsburgh, PA, USA
| | - José Luis Díaz-Ramón
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.,Department of Dermatology, Cruces University Hospital, Barakaldo, Spain
| | - Aintzane Apraiz
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain.,Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - Gorka Pérez-Yarza
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain.,Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - Pilar Ariadna Ezkurra
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain.,Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - Cristina Penas
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain
| | - Ana Sánchez-Diez
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.,Department of Dermatology, Basurto University Hospital, Bilbao, Spain
| | | | - Jesús Gardeazabal
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.,Department of Dermatology, Cruces University Hospital, Barakaldo, Spain
| | - Rosa Izu
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.,Department of Dermatology, Basurto University Hospital, Bilbao, Spain
| | - Karmele Mujika
- Department of Medical Oncology, Onkologikoa Hospital, Donostia, Spain.,Biodonostia Institute, Donostia, Spain
| | - Jesús Cortés
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - Aintzane Asumendi
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain.,Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - María Dolores Boyano
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, UPV/EHU, Leioa, Spain.,Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| |
Collapse
|
10
|
Fernández-de-Misa R, Hernández-Machín B, Combalía A, García Muret MP, Servitje O, Muniesa C, Gallardo F, Pujol RM, Martí RM, Ortiz-Brugués A, Maroñas-Jiménez L, Ortiz-Romero PL, Blanch Rius L, Izu R, Román C, Cañueto J, Blanes M, Morillo M, Bastida J, Peñate Y, Pérez Gala S, Espinosa Lara P, Pérez Gil A, Estrach T. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J Eur Acad Dermatol Venereol 2019; 34:762-768. [PMID: 31591786 DOI: 10.1111/jdv.16006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 09/25/2019] [Indexed: 11/29/2022]
Abstract
BACKGROUND Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking. OBJECTIVE To identify prognostic factors for specific survival in patients with PCALCL. METHODS Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed. RESULTS One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI: 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P < 0.001). Nodal progression was an independent predictive parameter for shorter survival (P = 0.011). CONCLUSION Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL.
Collapse
Affiliation(s)
- R Fernández-de-Misa
- Department of Dermatology and Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - B Hernández-Machín
- Department of Dermatology, Sefton Suite, DMC Healthcare, NHS Trust Liverpool, Liverpool, UK
| | - A Combalía
- Department of Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain
| | - M P García Muret
- Department of Dermatology, Hospital Santa Creu i Sant Pau, UAB, Barcelona, Spain
| | - O Servitje
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - C Muniesa
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - F Gallardo
- Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - R M Pujol
- Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - R M Martí
- Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain.,Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - A Ortiz-Brugués
- Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain
| | - L Maroñas-Jiménez
- Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - L Blanch Rius
- Department of Dermatology, Hospital de Basurto, Bilbao, Spain
| | - R Izu
- Department of Dermatology, Hospital de Basurto, Bilbao, Spain
| | - C Román
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - J Cañueto
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - M Blanes
- Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
| | - M Morillo
- Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - J Bastida
- Department of Dermatology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain
| | - Y Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de G.C, Spain
| | - S Pérez Gala
- Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - P Espinosa Lara
- Department of Dermatology, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
| | - A Pérez Gil
- Department of Dermatology, Hospital Virgen de Valme, Sevilla, Spain
| | - T Estrach
- Department of Dermatology, Hospital Clínico, IDIBAPS, University of Barcelona, Barcelona, Spain
| |
Collapse
|
11
|
Cabello I, Alia P, Pintó X, Muniesa C, Fernandez-de-Misa R, Peñate Y, Morillo M, Perez-Farriols A, Estrach T, Izu R, Gallardo F, Román C, Cervigón I, Ortiz-Brugues A, Ortiz-Romero PL, Servitje O. Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. JAMA Dermatol 2019; 154:1424-1431. [PMID: 30422238 DOI: 10.1001/jamadermatol.2018.3679] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Importance Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Despite standard prophylactic measures, there is a wide variability in the severity of this complication, which could be associated with both genetic and environmental factors. Objectives To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile. Design, Setting, and Participants This case series study was conducted in 12 university referral hospitals in Spain from September 17, 2014, to February 6, 2015. One hundred twenty-five patients with a confirmed diagnosis of CTCL who had received bexarotene therapy for at least 3 months were enrolled. Nine patients were excluded owing to missing analytic triglyceride level data, leaving a study group of 116 patients. Data on demographic and cardiovascular risk factor were collected, and a complete blood analysis, including lipid profile and genetic analysis from a saliva sample, was performed. Main Outcomes and Measures Primary outcomes were the maximal triglyceride levels reported in association with the minor alleles of the polymorphisms studied. Results Among 116 patients, the mean (SD) age was 61.2 (14.7) years, 69 (59.5%) were men, and 85 (73.2%) had mycosis fungoides, the most prevalent form of CTCL. During bexarotene therapy, 96 patients (82.7%) experienced hypertriglyceridemia, which was severe or extreme in 8 of these patients (8.3%). Patients who carried minor alleles of the polymorphisms did not show significant differences in baseline triglyceride concentrations. After bexarotene treatment, carriers of at least 1 of the 2 minor alleles of APOA5 c.-1131T>C and APOC3 c.*40C>G showed lower levels of triglycerides than noncarriers (mean [SD], 241.59 [169.91] vs 330.97 [169.03] mg/dL, respectively; P = .02). Conclusions and Relevance These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile.
Collapse
Affiliation(s)
- Irene Cabello
- Cardiovascular Risk Unit, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - Pedro Alia
- Clinical Genetics Laboratory, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - Xavier Pintó
- Cardiovascular Risk Unit, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - Cristina Muniesa
- Dermatology Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - Ricardo Fernandez-de-Misa
- Dermatology Department, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
| | - Yerai Peñate
- Dermatology Department, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
| | - Mercedes Morillo
- Dermatology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain
| | | | - Teresa Estrach
- Dermatology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - Rosa Izu
- Dermatology Department, Hospital Universitario de Basurto, Bilbao, Spain
| | | | - Concepción Román
- Dermatology Department, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Iván Cervigón
- Dermatology Department, Hospital Nuestra Señora del Prado, Talavera, Spain
| | | | - Pablo L Ortiz-Romero
- Dermatology Department, Hospital Universitario 12 de Octubre, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| | - Octavio Servitje
- Dermatology Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| |
Collapse
|
12
|
Fernández-de-Misa R, Hernández-Machín B, Servitje O, Valentí-Medina F, Maroñas-Jiménez L, Ortiz-Romero PL, Sánchez Schmidt J, Pujol RM, Gallardo F, Pau-Charles I, García Muret MP, Pérez Gala S, Román C, Cañueto J, Blanch Rius L, Izu R, Ortiz-Brugués A, Martí RM, Blanes M, Morillo M, Sánchez P, Peñate Y, Bastida J, Pérez Gil A, Lopez-Lerma I, Muniesa C, Estrach T. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol 2017; 43:137-143. [DOI: 10.1111/ced.13256] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/29/2016] [Indexed: 11/30/2022]
Affiliation(s)
- R. Fernández-de-Misa
- Department of Dermatology and Research Unit; Hospital Universitario Nuestra Señora de Candelaria; Santa Cruz de Tenerife Spain
| | - B. Hernández-Machín
- Department of Dermatology; Clínica Buenaderma; Las Palmas de Gran Canaria Spain
| | - O. Servitje
- Department of Dermatology; Hospital Universitari de Bellvitge; IDIBELL; Barcelona Spain
| | - F. Valentí-Medina
- Department of Dermatology; Hospital Universitari de Bellvitge; IDIBELL; Barcelona Spain
| | - L. Maroñas-Jiménez
- Department of Dermatology; Hospital Universitario 12 de Octubre, i+12 Research Institute; Universidad Complutense Madrid; Madrid Spain
| | - P. L. Ortiz-Romero
- Department of Dermatology; Hospital Universitario 12 de Octubre, i+12 Research Institute; Universidad Complutense Madrid; Madrid Spain
| | - J. Sánchez Schmidt
- Department of Dermatology; Hospital del Mar; Universitat Autónoma de Barcelona; Barcelona Spain
| | - R. M. Pujol
- Department of Dermatology; Hospital del Mar; Universitat Autónoma de Barcelona; Barcelona Spain
| | - F. Gallardo
- Department of Dermatology; Hospital del Mar; Universitat Autónoma de Barcelona; Barcelona Spain
| | - I. Pau-Charles
- Department of Dermatology; Hospital Clínico; University of Barcelona; IDIBAPS; Barcelona Spain
| | - M. P. García Muret
- Department of Dermatology; Hospital Santa Creu i Sant Pau; UAB; Barcelona Spain
| | - S. Pérez Gala
- Department of Dermatology; Hospital Universitario Ramón y Cajal; Madrid Spain
| | - C. Román
- Department of Dermatology; Hospital Universitario de Salamanca; Salamanca Spain
| | - J. Cañueto
- Department of Dermatology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Blanch Rius
- Department of Dermatology; Hospital de Basurto; Bilbao Spain
| | - R. Izu
- Department of Dermatology; Hospital de Basurto; Bilbao Spain
| | - A. Ortiz-Brugués
- Department of Dermatology; IRBLleida, Hospital Universitari Arnau de Vilanova; Lleida Spain
| | - R. M. Martí
- Department of Dermatology; IRBLleida, Hospital Universitari Arnau de Vilanova; Lleida Spain
| | - M. Blanes
- Department of Dermatology; Hospital General Universitario de Alicante; Alicante Spain
| | - M. Morillo
- Department of Dermatology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - P. Sánchez
- Department of Dermatology; Hospital de León; León Spain
| | - Y. Peñate
- Department of Dermatology; Complejo Hospitalario Universitario Insular Materno-Infantil; Gran Canaria, Las Palmas de Gran Canaria Spain
| | - J. Bastida
- Department of Dermatology; Hospital Universitario Dr. Negrín; Las Palmas de Gran Canaria Spain
| | - A. Pérez Gil
- Department of Dermatology; Hospital Virgen de Valme; Sevilla Spain
| | - I. Lopez-Lerma
- Department of Dermatology; Hospital Universitari Vall d'Hebron; Barcelona Spain
| | - C. Muniesa
- Department of Dermatology; Hospital Universitari de Bellvitge; IDIBELL; Barcelona Spain
| | - T. Estrach
- Department of Dermatology; Hospital Clínico; University of Barcelona; IDIBAPS; Barcelona Spain
| |
Collapse
|
13
|
Ortega-Martínez I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, Cortés J, García-Vázquez MD, Pérez-Yarza G, Izu R, Luís Díaz-Ramón J, de la Fuente IM, Asumendi A, Boyano MD. Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma. Int J Cancer 2016; 139:1598-607. [PMID: 27216146 PMCID: PMC5089559 DOI: 10.1002/ijc.30202] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Accepted: 05/11/2016] [Indexed: 01/03/2023]
Abstract
Like many cancers, an early diagnosis of melanoma is fundamental to ensure a good prognosis, although an important proportion of stage I-II patients may still develop metastasis during follow-up. The aim of this work was to discover serum biomarkers in patients diagnosed with primary melanoma that identify those at a high risk of developing metastasis during the follow-up period. Proteomic and mass spectrophotometry analysis was performed on serum obtained from patients who developed metastasis during the first years after surgery for primary tumors and compared with that from patients who remained disease-free for more than 10 years after surgery. Five proteins were selected for validation as prognostic factors in 348 melanoma patients and 100 controls by ELISA: serum amyloid A and clusterin; immune system proteins; the cell adhesion molecules plakoglobin and vitronectin and the antimicrobial protein dermcidin. Compared to healthy controls, melanoma patients have high serum levels of these proteins at the moment of melanoma diagnosis, although the specific values were not related to the histopathological stage of the tumors. However, an analysis based on classification together with multivariate statistics showed that tumor stage, vitronectin and dermcidin levels were associated with the metastatic progression of patients with early-stage melanoma. Although melanoma patients have increased serum dermcidin levels, the REPTree classifier showed that levels of dermcidin <2.98 μg/ml predict metastasis in AJCC stage II patients. These data suggest that vitronectin and dermcidin are potent biomarkers of prognosis, which may help to improve the personalized medical care of melanoma patients and their survival.
Collapse
Affiliation(s)
- Idoia Ortega-Martínez
- Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain
| | - Jesús Gardeazabal
- Department of Dermatology, Ophthalmology and Otorhinolaryngology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - Asier Erramuzpe
- BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - Ana Sanchez-Diez
- Department of Dermatology, Ophthalmology and Otorhinolaryngology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - Jesús Cortés
- Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain.,Ikerbasque: The Basque Foundation for Science, Bilbao, Spain
| | - María D García-Vázquez
- Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain
| | - Gorka Pérez-Yarza
- Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - Rosa Izu
- Department of Dermatology, Ophthalmology and Otorhinolaryngology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - Jose Luís Díaz-Ramón
- Department of Dermatology, Ophthalmology and Otorhinolaryngology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - Ildefonso M de la Fuente
- Institute of Parasitology and Biomedicine Lopez-Neyra, Parque Tecnológico Ciencias De La Salud, Avenida Del Conocimiento S/N, Armilla, Granada, Spain
| | - Aintzane Asumendi
- Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| | - María D Boyano
- Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.,BioCruces Health Research Institute, Plaza De Cruces S/N, Barakaldo, Bizkaia, Spain
| |
Collapse
|
14
|
Carrascosa J, Belinchón I, de-la-Cueva P, Izu R, Luelmo J, Ruiz-Villaverde R. Expert Recommendations on Treating Psoriasis in Special Circumstances. Actas Dermo-Sifiliográficas (English Edition) 2015. [DOI: 10.1016/j.adengl.2015.03.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
15
|
Carrascosa JM, Belinchón I, de-la-Cueva P, Izu R, Luelmo J, Ruiz-Villaverde R. Expert recommendations on treating psoriasis in special circumstances. Actas Dermosifiliogr 2015; 106:292-309. [PMID: 25595327 DOI: 10.1016/j.ad.2014.11.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2014] [Revised: 10/26/2014] [Accepted: 11/09/2014] [Indexed: 01/09/2023] Open
Abstract
INTRODUCTION AND OBJECTIVES A great amount of information on systemic and biologic therapies for moderate to severe psoriasis is now available. However, applying the evidence in numerous clinical scenarios has engendered debate; under these circumstances, the consensus of experts is useful. MATERIAL AND METHODS A scientific committee systematically reviewed the literature relevant to 5 clinical scenarios. An online Delphi survey of dermatologists with experience treating moderate to severe psoriasis was then carried out in order to shed light on questions that remained unresolved by the available evidence. RESULTS Twenty-three dermatologists responded to the survey and consensus was reached on 37 (56%) of the 66 statements proposed. These results led to consensus on various clinical situations even though firm evidence was lacking. Thus, intermittent therapeutic regimens and strategies for reducing the intensity of treatment are considered appropriate for optimizing biologic treatment and reducing costs. The measurement of drug and antidrug antibody levels should be included routinely when following patients on biologics to treat psoriasis. Concomitant psoriatic arthritis or a history of cardiovascular conditions will influence the choice of biologic; in these situations, an agent with anti-tumor necrosis factor properties will be preferred. Tailored management is important when the patient is pregnant or intends to conceive; drug half-life and disease severity are important factors to take into consideration in these scenarios. CONCLUSIONS A combination of systematic review of the literature and structured discussion of expert opinion facilitates decision-making in specific clinical scenarios.
Collapse
Affiliation(s)
- J M Carrascosa
- Servei de Dermatologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.
| | - I Belinchón
- Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España
| | - P de-la-Cueva
- Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, España
| | - R Izu
- Servicio de Dermatología, Hospital Universitario Basurto, Universidad del País Vasco, Bilbao, España
| | - J Luelmo
- Servicio de Dermatología, Hospital Universitario ParcTaulí de Sabadell, Universidad Autónoma de Barcelona, Barcelona, España
| | - R Ruiz-Villaverde
- Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Granada, España
| |
Collapse
|
16
|
Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, Estrach T, Fernández-Guarino M, Calzado L, Acebo E, Gallardo F, Salar A, Izu R, Ortiz-Romero PL, Pujol RM, Fernández-de-Misa R. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol 2012; 167:174-9. [PMID: 22356294 DOI: 10.1111/j.1365-2133.2012.10902.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients. OBJECTIVES To evaluate the effectiveness, tolerance and adverse effects of ILR in patients with follicle centre (FCL) and marginal zone (MZL) PCBL. METHODS This was an epidemiological observational multicentre study of patients with PCBL treated with ILR. RESULTS Seventeen patients with MZL and 18 with FCL PCBL were included. The median number of lesions treated was two per patient. The treatment regimen used in 74% of the patients was a course of three injections in a single week at 1-month intervals. The dose per lesion and day of treatment was 10 mg in 71% of the patients. The median cumulative dose of rituximab per lesion was 60 mg (range 13-270) and per patient was 150 mg (range 20-360 mg). Complete response (CR) and partial response were achieved in 71% and 23% of patients, respectively. The median time to CR in patients who received 10 mg of ILR per lesion was 8 weeks. Similar response rates were observed in MZL and FCL. Median disease-free survival was 114·1 weeks. No parameters that significantly predicted CR were identified. Adverse reactions were recorded in 19 patients; the most frequent was localized pain at the injection site. Median follow-up was 21 months. CONCLUSIONS Intralesional rituximab is a well-tolerated and effective treatment for FCL and MZL PCBL. It should be considered a useful alternative in patients with recurrent lesions and in which the sequelae of radiotherapy or surgery would be significant.
Collapse
Affiliation(s)
- Y Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Las Palmas de GC, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Hernánz JM, Sánchez-Regaña M, Izu R, Mendiola V, García-Calvo C. Clinical and Therapeutic Evaluation of Patients with Moderate to Severe Psoriasis in Spain: The Secuence Study. Actas Dermosifiliogr 2012; 103:897-904. [PMID: 22748300 DOI: 10.1016/j.ad.2012.04.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2011] [Revised: 04/26/2012] [Accepted: 04/30/2012] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND: Evaluation of disease severity is considered essential in the optimal management of psoriasis. OBJECTIVES: To describe the clinical characteristics and therapeutic profile of patients with moderate to severe psoriasis in Spain and to assess the impact of the disease on the patients' quality of life. MATERIALS AND METHODS: This was an observational, cross-sectional study carried out in 90 dermatology units in Spain in 2009. We included 442 patients diagnosed with moderate to severe psoriasis who had started treatment with systemic agents, phototherapy, and/or topical treatments between 2004 and 2006. RESULTS: More severe psoriasis was significantly associated with the following: longer disease duration; higher prevalence of concomitant disease; greater involvement of the nails, scalp, flexures, palms, and soles; and poorer quality of life. In the 5 years before the start of the study, 68% of the patients had received conventional systemic treatments, 39.1% biologic agents, and 22.3% phototherapy. At present, 57.5% of the patients are being treated with biologic agents, 32.6% with conventional systemic treatments, and 11% with phototherapy. CONCLUSIONS: Severity of psoriasis was associated with a marked impact on quality of life. Regardless of disease severity, psychiatric comorbidity was the strongest predictor of poor quality of life. On average, patients had received other treatments, such as conventional systemic treatments or phototherapy, for more than 2 years before switching to biologic agents for the first time.
Collapse
Affiliation(s)
- J M Hernánz
- Departamento Dermatología, Hospital Infanta Leonor, Madrid, España
| | | | | | | | | |
Collapse
|
18
|
Betlloch I, Izu R, Lleonart M, Ferrer M, Ferrando J. Actitud del paciente adulto con dermatitis atópica frente a su patología y tratamiento. Estudio ACTIDA. Actas Dermo-Sifiliográficas 2010. [DOI: 10.1016/j.ad.2009.07.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
19
|
Betlloch I, Izu R, Lleonart M, Ferrer M, Ferrando J. [Attitude of the adult patient with atopic dermatitis to the disease and its treatment: the ACTIDA Study]. Actas Dermosifiliogr 2010; 101:143-150. [PMID: 20223156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
OBJECTIVE To determine the attitude of adult patients with atopic dermatitis (AD) to their disease and its treatment. MATERIAL AND METHODS A multicenter, cross-sectional study was performed in patients with at least 2 outbreaks of AD in the previous year. RESULTS Two hundred twenty-seven dermatologists recruited 1441 analyzable patients, the majority women, with a mean of 3.6 outbreaks per year. Most of the patients (97.2%) indicated that they always or sometimes requested medical evaluation of a new outbreak. In the most recent outbreak, 72.2% had used combined therapy, regardless of the severity of the episode; 2-drug combinations were the most common. The majority of dermatologists prescribed combined therapy, most commonly a 2-drug combination for mild or minimal disease, and 3 or more drugs for moderate to very severe outbreaks. CONCLUSIONS Treatments used by patients for an outbreak of AD are similar to those prescribed by dermatologists in recent outbreaks.
Collapse
Affiliation(s)
- I Betlloch
- Servicio de Dermatología, Hospital General de Alicante, Alicante, Spain
| | | | | | | | | |
Collapse
|
20
|
Richard C, Bermúdez A, Izu R. Graft-versus-lymphoma effect. Br J Haematol 2009; 149:166. [PMID: 20015300 DOI: 10.1111/j.1365-2141.2009.08001.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Carlos Richard
- Servicio de Hematología, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander 39008.
| | | | | |
Collapse
|
21
|
Nieto-Rementería N, Pérez-Yarza G, Boyano M, Apraiz A, Izu R, Díaz-Pérez J, Asumendi A. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol 2009; 160:519-26. [DOI: 10.1111/j.1365-2133.2008.08931.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
22
|
Pérez-Barrio S, Izu R, García-Ruiz J, Acebo E, Martínez De Lagrán Z, Díaz-Pérez J. Trasplante autólogo de progenitores hematopoyéticos seguido de bexaroteno oral en paciente con micosis fungoide avanzada. Actas Dermo-Sifiliográficas 2008. [DOI: 10.1016/s0001-7310(08)74742-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
23
|
Pérez-Barrio S, Izu R, García-Ruiz JC, Acebo E, Martínez de Lagrán Z, Díaz-Pérez JL. [Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides]. Actas Dermosifiliogr 2008; 99:560-564. [PMID: 18682170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
We describe the case of a 17-year-old patient with rapidly progressing and aggressive mycosis fungoides, with multiple cutaneous tumors and large cell transformation. She was initially treated with 3 cycles of high-dose chemotherapy with mega-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) without response, leading to the decision to undertake autologous hematopoietic stem cell transplantation. Partial remission of the disease was achieved with this treatment and subsequent introduction of oral bexarotene led to complete remission, which has been maintained for more than 3 years with good tolerance of oral therapy. We discuss the advantages and disadvantages of autologous hematopoietic stem cell transplantation and the use of oral bexarotene.
Collapse
Affiliation(s)
- S Pérez-Barrio
- Servicio de Dermatología. Hospital de Cruces. Baracaldo. Vizcaya. España.
| | | | | | | | | | | |
Collapse
|
24
|
Abstract
INTRODUCTION The choice of treatment in cutaneous T-cell lymphomas (CTCLs) depends on the clinical stage of the disease and the patient's general condition. To date, there is no curative treatment for this disease, and the objective is to control the symptoms and prevent the disease from progressing. Bexarotene is an X receptor-specific retinoid with anti-tumor activity. Its use as treatment for CTCLs refractory to at least one prior systemic therapy has been approved by the FDA. PATIENTS AND METHODS We carried out a descriptive study of 9 patients treated with bexarotene in the Lymphoma Unit of our department. We analyzed the clinical characteristics of the patients and the efficacy of the treatment, and we collected data on the side effects that appeared. RESULTS The overall response to the treatment was 44.4% (4/9). 2 patients had full remission and 2 had partial remission. Tolerance to the treatment was good, and the most frequent side effects were hypertriglyceridemia, hypercholesterolemia and central hypothyroidism. CONCLUSIONS Even though this is a series of only 9 patients, the results that we obtained are similar to ones previously described. Bexarotene is an effective therapeutic option in this heterogeneous group of diseases.
Collapse
Affiliation(s)
- Olatz Lasa
- Servicio de Dermatología, Hospital de Cruces, Bilbao, Spain.
| | | | | | | | | |
Collapse
|
25
|
García-Vázquez MD, Boyano MD, Cañavate ML, Gardeazabal J, de Galdeano AG, López-Michelena T, Ratón JA, Izu R, Díaz-Ramón JL, Díaz-Pérez JL. Interleukin-2 enhances the growth of human melanoma cells derived form primary but not from metastatic tumours. Eur Cytokine Netw 2000; 11:654-61. [PMID: 11125310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Previously, we demonstrated that in vitro treatment of B16F10 murine melanoma cells with interleukin-2 (IL-2) enhances proliferation and metastasis. To further investigate the role played by IL-2 in human melanomas, we studied the expression of IL-2/IL-2 receptor and the effect of IL-2 on the proliferation of melanoma cell lines derived from primary (A375 and RMS cell lines) and metastatic (Hs294T cell line) tumours. We found a constitutive expression of cytoplasmic IL-2 and alpha, beta and gamma-subunits of the IL-2R on the surface of the three melanoma cell lines. The presence of IL-2 in the culture increased the proliferation rate in A375 and RMS cell lines, but no effect was observed in Hs294T metastatic cells. Biologically active IL-2 could be found in the supernatant of the three melanoma cell lines, particularly in A375 and RMS cells, in which an inhibition of the proliferation rate was observed when IL-2 was blocked. Moreover, the combination of anti-IL-2R beta and anti-IL-2R gamma blocking antibodies induced a significant down-regulation of cell proliferation in the three melanoma cell lines, and the combination of anti-IL-2R alpha, anti-IL-2R beta and anti-IL-2R gamma blocking antibodies inhibited IL-2-mediated growth stimulation in A375 and Hs294T cell lines. In RMS cells, a more significant effect was observed when only IL-2R gamma was blocked. Finally, exogenous IL-2 modulated the IL-2 endogenously produced by melanoma cells. These data show that IL-2 may modulate the growth of melanoma cells through autocrine or/and paracrine mechanisms.
Collapse
Affiliation(s)
- M D García-Vázquez
- Department of Cell Biology and Morphological Sciences, School of Medicine and Dentistry, University of the Basque Country, Leioa 48940, Bizkaia, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000; 83:847-52. [PMID: 10970683 PMCID: PMC2374688 DOI: 10.1054/bjoc.2000.1402] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Serum soluble interleukin-2 receptor (sIL-2R), intercellular adhesion molecule-1 (sICAM-1) and interleukin-10 (IL-10) have each been reported as useful markers for melanoma progression. To evaluate the clinical relevance of these three markers, we simultaneously analysed their serum levels in patients with melanoma. A longitudinal study with a 3-year follow-up was performed and different stages of the disease were considered. Mean values of sIL-2R were significantly higher than in normal controls in all stages and correlated with the disease progression. The prognosis of patients with levels > 529 U/ml of sIL-2R was significantly poorer than in patients with sIL-2R levels < 529 U/ml. Levels of sICAM-1 were also elevated in melanoma patients, specially at the time of the metastatic disease. Serum IL-10 levels were more frequently detectable in the patients that developed metastasis during follow-up, and the prognosis of patients with detectable IL-10 levels was significantly poorer than in those patients with IL-10 undetected levels. Statistical analysis based on Logistic and Cox regression models showed that only sex, stage and sIL-2R value are factors significantly associated with metastatic progression. Moreover, high levels of sIL-2R could be a risk factor for malignant progression in melanoma.
Collapse
Affiliation(s)
- M D Boyano
- Department of Cell Biology and Morphological Sciences, School of Medicine and Dentistry, University of the Basque Country, Leioa, Bizkaia, 48940, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
We described an unusual male patient with two disfiguring diseases, benign symmetric lipomatosis and giant rhinophyma, which gave him a grotesque appearance. His physical appearance had isolated him from the rest of society and was probably the main reason for his alcohol abuse.
Collapse
Affiliation(s)
- R Izu
- Department of Dermatology, Hospital de Cruces, Bilbao, País Basco, Spain
| | | | | | | | | |
Collapse
|
28
|
|
29
|
Affiliation(s)
- D Manzano
- Dermatology Department, Cruces University Hospital, Vizcaya, Spain
| | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- A Aguirre
- Servicio de Dermatología, Hospital Universitario de Cruces, Bilbao, Vizcaya, Spain
| | | | | | | | | |
Collapse
|
31
|
Affiliation(s)
- R Izu
- Dermatology Department, Hospital de Cruces, Bilbao, Spain
| | | | | | | |
Collapse
|
32
|
Affiliation(s)
- A Aguirre
- Department of Dermatology, Hospital de Cruces, University of the Basque Country, Vizcaya, Spain
| | | | | | | | | |
Collapse
|
33
|
Arregui MA, Ratón JA, Landa N, Izu R, Eizaquirre X, Díaz-Pérez JL. Bazex's syndrome (acrokeratosis paraneoplastica)--first case report of association with a bladder carcinoma. Clin Exp Dermatol 1993; 18:445-8. [PMID: 8252768 DOI: 10.1111/j.1365-2230.1993.tb02247.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Bazex's acrokeratosis paraneoplastica is a clinically well-defined entity consisting of a distal erythemato-squamous eruption and nail dystrophy. It is always associated with neoplasia, mainly squamous carcinomas of the upper digestive and respiratory tracts; therefore, Bazek's acrokeratosis is considered to be a specific marker of internal malignancy. Two new cases of this syndrome are reported. The first was in a 41-year-old man with a squamous cell carcinoma of the oesophagus, the second in a 73-year-old man who presented with a transitional cell bladder carcinoma, an association not previously reported.
Collapse
Affiliation(s)
- M A Arregui
- Department of Dermatology, Cruces Hospital, Bilbao, Spain
| | | | | | | | | | | |
Collapse
|
34
|
Gardeazabal J, Gonzalez M, Izu R, Gil N, Aguirre A, Diaz-Perez JL. Phenofibrate-induced lichenoid photodermatitis. Photodermatol Photoimmunol Photomed 1993; 9:156-8. [PMID: 8318433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Phenofibrate is an hypolipemiant drug derived from fibric acid. Cutaneous side effects such as pruritus, rash, urticarial lesions and some rare cases of photosensitivity have been described (1-3). The reported photosensitivity cases are clinically described as eczematous (1-3); some have been reproduced by photopatch-testing (2, 3). We studied a patient with a clinical and histopathological lichenoid eruption over light-exposed areas clearly related to phenofibrate therapy for an essential hypercholesterolemia.
Collapse
Affiliation(s)
- J Gardeazabal
- Department of Dermatology, Hospital de Cruces, Vizcaya, Spain
| | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- R Izu
- Dermatology Department, Hospital de Cruces, Bilbao, Vizcaya, Spain
| | | | | | | | | |
Collapse
|
36
|
Affiliation(s)
- A Aguirre
- Department of Dermatology, Hospital de Cruces, University of the Basque Country, Bilbao, Vizcaya, Spain
| | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- A Aguirre
- Department of Dermatology, Hospital de Cruces, University of the Basque Country, Bilbao Vizcaya, Spain
| | | | | | | |
Collapse
|
38
|
Affiliation(s)
- R Izu
- Dermatology Department, Cruces Hospital, Bilbao, Spain
| | | | | | | | | |
Collapse
|
39
|
Affiliation(s)
- A Aguirre
- Dermatology Department, Hospital de Cruces, Bilbao, Spain
| | | | | | | | | |
Collapse
|
40
|
Izu R, Gardeazabal J, González M, Landa N, Ratón JA, Díaz-Pérez JL. Enoxacin-induced photosensitivity: study of two cases. Photodermatol Photoimmunol Photomed 1992; 9:86-8. [PMID: 1489723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Enoxacin is a second-generation quinolone derivative recently introduced in Spain. Its activity comes through the inhibition of bacterial DNA-gyrase and it has a good antibacterial capacity against a broad spectrum of gram-positive and gram-negative bacteria. It is presumed to be less toxic than the rest of the quinolones and its use is increasing, specially to treat infections of the urogenital tract. Cases of photosensitivity to enoxacin have been very rarely reported. We describe 2 patients with photosensitivity reactions due to this drug.
Collapse
Affiliation(s)
- R Izu
- Department of Dermatology, Hospital de Cruces, Bilbao, Spain
| | | | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- R Izu
- Dermatology Department, Cruces Hospital, Bilbao, Spain
| | | | | | | |
Collapse
|
42
|
Affiliation(s)
- R Izu
- Dermatology Department, Cruces Hospital, Bilbao, Spain
| | | | | | | |
Collapse
|